Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 7;13:778322. doi: 10.3389/fendo.2022.778322

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Prado-Wohlwend, del Olmo-García, Bello-Arques and Merino-Torres

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Patient number 5 in the [¹³¹I]MIBG table was treated first with [¹³¹I]MIBG and subsequently with PRRT. After 6 months of disease stability with [¹³¹I]MIBG, lung, lymph node, and the bone disease progressed. Subsequently, the patient received treatment with [¹⁷⁷Lu]Lu-DOTA-TATE, reaching disease stability of 10 months. Diagnostic functional imaging studies and post-therapy distribution scans of both therapies are shown. (A) Diagnostic scan with [¹²³I]MIBG in anterior and posterior planar projection. (B) Distribution scan after treatment with 7.4 GBq of [¹³¹I]MIBG in anterior and posterior planar projection. (C) ⁶⁸Ga-DOTA-SSA PET/CT maximum intensity projection (MIP). (D) Distribution scan after treatment with 8.1 GBq of [¹⁷⁷Lu]Lu-DOTA-TATE in anterior and posterior planar projection.